The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Pfizer has an asset utilization ratio of 30.27 percent. This indicates that the company is making $0.3 for each dollar of assets. An increasing asset utilization means that Pfizer Inc is more efficient with each dollar of assets it utilizes for everyday operations. Earning per share calculations of the firm is based on official Zacks consensus of 4 analysts regarding Pfizer's future annual earnings. Given the historical accuracy of 92.82%, the future earnings per share of the company is estimated to be 2.88 with the lowest and highest values of 2.82 and 2.95, respectively. Please note that this consensus of annual earnings estimates for Pfizer Inc is an estimate of EPS before non-recurring items and including employee stock options expenses.
The successful prediction of Pfizer
stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published
stock prices of traded companies, such as Pfizer Inc, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at
the intrinsic value of Pfizer based on Pfizer hews, social hype, general headline patterns, and widely used
predictive technical indicators. We also calculate exposure to Pfizer's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Pfizer's related companies.
Use Technical Analysis to project Pfizer expected Price
Pfizer technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Pfizer technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Pfizer trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions.
More Info...Pfizer Gross Profit
Pfizer Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Pfizer previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Pfizer Gross Profit growth over the last 10 years. Please check Pfizer's
gross profit and other
fundamental indicators for more details.
What is driving Pfizer Investor Appetite?
The small decline in market price for the last few months may encourage shareholders to take a closer look at the company as it closed today at a share price of
37.23 on
24,342,702 in trading volume. The company executives did not add much value to Pfizer investors in
June. However, diversifying your holdings with Pfizer Inc or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 30 days investing horizon is currently 2.0. The current volatility is consistent with the ongoing market swings in
June 2020 as well as with Pfizer unsystematic, company-specific events.
Cost of Revenue Breakdown
Pfizer Cost of Revenue is increasing over the years with stable fluctuation. Cost of Revenue is expected to dwindle to about 9.9
B. Cost of Revenue usually refers to the aggregate cost of goods produced and sold and services rendered during the reporting period. Pfizer Cost of Revenue is projected to increase significantly based on the last few years of reporting. The past year's Cost of Revenue was at 10.22 Billion
| 2013 | 9.59 Billion |
| 2014 | 9.58 Billion |
| 2015 | 9.65 Billion |
| 2016 | 12.32 Billion |
| 2017 | 11.23 Billion |
| 2018 | 11.25 Billion |
| 2019 | 10.22 Billion |
| 2020 | 9.95 Billion |
Pfizer has 88 percent chance to finish below $38 next week
Latest Market Risk Adjusted Performance is up to 0.1. Price may dip again. Pfizer Inc currently demonstrates below-verage downside deviation. It has Information Ratio of -0.06 and Jensen Alpha of -0.04. However, we do advice investors to further question Pfizer Inc expected returns to ensure all indicators are consistent with the current outlook about its relatively low value at risk.
Our Conclusion on Pfizer
Although some other companies in the drug manufacturers—general industry are either recovering or due for a correction, Pfizer may not be as strong as the others in terms of longer-term growth potentials. With a somewhat neutral outlook on your 30 days horizon, it may be better to hold off any trading activity and neither take in new shares of Pfizer nor short your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Pfizer.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Pfizer Inc. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com